Clearing House Whup Whup Hut

[PoemStone]

Estrella'sSizzlingHotStockPlays. StockO'holicsInvestingUniversity. CURX/QB:

http://investorshub.advfn.com/boards/board.aspx?board_id=21178
http://investorshub.advfn.com/boards/board.aspx?board_id=5322

CURX ~Curaxis Pharmaceutical Corporation~ dd
CURX.OB (Frankfurt: 8CX)

The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be
held on November 8th 2011. Please click here to download the proxy materials
and to vote:

[1]https://www.iproxydirect.com/index.php/CURX

About CURX.OB (Frankfurt: 8CX)

Curaxis Pharmaceutical Corporation is an emerging specialty pharmaceutical
company with a hormone drug product candidate for the treatment of Alzheimer's
disease and multiple cancers. Curaxis' therapeutic platform is based on the
hypothesis that many diseases of aging may be caused by age-related changes in
the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is
a hormonal endocrine feedback loop that controls development, reproduction and
aging in animals. This drug development platform is built on the premise that
hormones associated with this feedback loop are beneficial early in life, when
they promote growth and development, but are harmful later in life when the
mechanism for feedback is compromised, thereby leading to disease processes,
including pathologies associated with Alzheimer's disease and various cancers.

Click Here For Video: [2]http://blog.curaxispharma.com/media/
[3][rjqljCapture10.GIF]

CURX Security Details
Curaxis Pharmaceutical Corporation is a fully reporting SEC company, publicly
traded on the OTC Market under the symbol, "CURX", and within the OTCQB market
tier. As such, Business, operational and financial information on CURX is fully
transparent and available to public view.

Visit [4]http://www.otcmarkets.com/stock/CURX/quote for more information.

Market Value1 $5,357,650 a/o Nov 03, 2011
Shares Outstanding 76,537,861 a/o Aug 11, 2011
Float 16,238,300 a/o Sep 15, 2010
Authorized Shares 480,000,000 a/o Aug. 12 2011
Par Value 0.0001
(per otcmarkets)

Per FORM 10Q link listed below
As of August 11 , 2011, there were 76,537,861 shares outstanding of the
registrant's common stock.
Common stock, $0.0001 par value; 480,000 authorized; 72,216 and 76,474 shares
issued and outstanding at December 31, 2010 and June 30, 2011, respectively.

Transfer Agent
Direct Transfer, LLC.
500 Perimeter Park Drive Suite D
Suite D
Morrisville, NC, 27560
919-481-4000
www.issuerdirect.com
[e-mail]

10Q reported Aug 12, 2011 period ending Jun 30, 2011
[5]http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8096721

Shareholders of Record: 41 a/o Apr 15, 2010
SIC - Industry Classification: 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc.: 2008 and On July 30, 2010, the Company entered into an agreement
and plan of merger with Curaxis Pharmaceutical Corporation, a Nevada
corporation formed solely for the purpose of a name change. Pursuant to the
Short-Form Merger, the Company changed its name to Curaxis Pharmaceutical
Corporation ("Curaxis" or the "Company")

In February 2011, the Company was granted approval and listed its stock to
trade on the Frankfurt stock exchange ("FSE") under the symbol 8CX to expand
its global capital markets access.

Security Notes
Capital Change=shs increased by 91 for 1 split. Ex-date=01/12/2010. Rec
date=12/09/2009. Pay date=01/11/2010
Company Notes
Formerly=Auto Search Cars, Inc. until 9-2010

Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com

CURX Products & Services
CURX Pipeline

Our therapeutic platform is based on the hypothesis that many diseases of aging
may be caused by age-related dysregulation of the
hypothalamic-pituitary-gonadal (HPG) axis. This platform is built on the
premise that hormones associated with this axis are beneficial early in life,
when they promote growth and development, but are harmful later in life when
the mechanism for feedback is compromised, thereby leading to disease
processes, including pathologies associated with Alzheimer's disease and
various cancers. We believe our discovery of a duplicate HPG axis at the
cellular level in brain tissue from Alzheimer's patients and in multiple tumors
will enable us to develop significant new treatments for Alzheimer's disease as
well as many cancers.

CURX Alzheimer's Disease Program
Leuprolide acetate, a peptide hormone, has been widely used over the past
twenty years for the treatment of a number of hormone-related disorders, most
notably prostate cancer and endometriosis and precocious puberty, and has a
well-established safety profile. Voyager has conducted extensive preclinical
and clinical studies exploring the use of leuprolide acetate for the treatment
of Alzheimer's disease in mild-to-moderate patients. The results to date are
very encouraging and point especially to a potentially significant new
treatment for women with Alzheimer's disease.

Women represent approximately two-thirds of Alzheimer's patients. Men present
greater challenges in the use of leuprolide to treat Alzheimer's disease
because leuprolide suppresses their production of testosterone, which could
necessitate patient self-administration of supplemental testosterone and which
can lead to wide swings in testosterone blood serum levels. Therefore, in the
near-term, we plan to concentrate our development efforts on the use of
leuprolide acetate to treat women, although we will continue our efforts to
better understand mechanisms that might lead to optimum outcomes in men.

This Video is Patrick Smith Of Curaxis Pharmaceutical Corporation - Alzheimer
Disease
Lists him as CEO but he is no longer the CEO, but it explains Alzheimer's and
the company Brilliantly!

[6][gif]

[7]http://www.youtube.com/watch?v=XdMmQ6ppDnU

CURX Oncology Program
We have conducted an extensive preclinical research program in the use of
leuprolide acetate to treat a number of cancers, including hor mone refractory
prostate cancer, brain cancers, kidney cancer, pancreatic cancer and
non-small-cell lung cancer.

Our work in oncology is based on new insights into the growth of cancer cells
that have been discovered by our scientists. In particular, our scientific
findings relating to autocrine-paracrine signaling and the replication of the
hypothalamic-pituitary-gonadal axis (the HPG axis) inside of cancer cells point
to a previously unknown mechanism that drives the growth of cancer cells and an
entirely new method of attacking those cancer cells; i.e., using high doses of
leuprolide acetate to eliminate the gonadotropins that may be driving the
growth of those cells.

Our preclinical testing of this new treatment approach has produced extremely
encouraging results. In both in vitro and in vivo experiments, we have
demonstrated a potentially important new therapy for the treatment of a number
of cancers.

We plan to use the same compound for our various cancer Phase II clinical
trials as we are using for clinical trials of VP4896. Since we have completed
Phase I safety trials of VP4896, we believe that we will be able to commence
our clinical programs for various cancers with Phase II clinical trials instead
of Phase I safety trials. However, the FDA will have to agree to the
commencement of these clinical programs with Phase II clinical trials when we
submit our Investigational New Drug Applications, or INDs, to the FDA.

History
Curaxis' history dates to an insight from the mid-1990's concerning how changes
in various hormone levels impact our health as we age. Most everyone knows
that, as we age, our hormone levels change. In particular, it is well known
that as we age, levels of estrogen decline precipitously in women, leading to
menopause, and levels of testosterone gradually decline in men, leading to
andropause. However, while a great deal of research has previously been devoted
to the effects of declining estrogen and testosterone on our health, including
our mental abilities, Curaxis has taken this research in a broader direction.

Specifically, Curaxis was founded in 2001 (as Voyager Pharmaceutical Corp.) to
take a step back from a singular focus on estrogen and testosterone to examine
the entire HPG axis, which regulates production of estrogen and testosterone
throughout our lives. Curaxis' initial hypothesis was that changes in the
levels of hormones in this axis other than estrogen and testosterone play a key
role in various diseases of aging. During 2001 and the years that immediately
followed, Curaxis devoted substantial research to testing this hypothesis. Also
during 2001, Curaxis was awarded a broad patent covering its unique approach to
the treatment of Alzheimer's.

As a result of Curaxis' research, it became increasingly clear that one hormone
of the HPG axis, called luteinizing hormone or LH, may play a central role in
the pathologies that lead to Alzheimer's as well as other diseases of aging,
including many cancers. Levels of LH increase dramatically as women enter
menopause and increase substantially in men as they age and testosterone
production declines. In numerous preclinical studies, Curaxis' research showed
that these increased levels of LH were likely a key contributor to developing
Alzheimer's.

Developing A Focus
Having determined that high levels of LH represented a potential cause of
Alzheimer's, Curaxis then focused on using leuprolide acetate, which eliminates
or dramatically reduces LH levels, as a treatment for Alzheimer's. Curaxis'
focus on LH followed two parallel paths.

First, in 2002, Curaxis entered into an agreement with Durect Corporation to
develop a proprietary implant that would release leuprolide acetate at targeted
levels over a two month dosing period. Work on development of this implant
commenced in 2002 and culminated in 2005 with a successful Phase 1 trial of the
safety and tolerability of the implant.

Second, because leuprolide acetate had been used for many years to treat other
diseases, including prostate cancer, in early 2003 Curaxis commenced a Phase 2
clinical trial to treat mild-to-moderate Alzheimer's in women, using a
commercially available dose of leuprolide. In addition, in late 2003 Curaxis
commenced a Phase 2 clinical trial to treat mild-to-moderate Alzheimer's in
men, again using a commercially available dose of leuprolide.

This parallel path enabled Curaxis to significantly shorten development for its
Alzheimer's candidate. As a result, by mid-2005, Curaxis had successfully
completed dosing in the Phase 1 trial of its proprietary implant developed with
Durect, which Curaxis calls Memryte, and had also completed its Phase 2 trial
of leuprolide in women. The results of both of these trials were encouraging
and Curaxis began making plans for Phase 3 trials of Memryte. Based on FDA
filings and a meeting with the FDA in August 2005, Curaxis launched its Phase 3
trials of Memryte in September 2005.

Also in September 2005, Curaxis (then Voyager Pharmaceutical) filed for its
initial public offering, in order to raise sufficient funds for its Phase 3
trials. Based on the strength of its preclinical and clinical data and its
management, it was anticipated that a successful IPO would follow later in
2005. Unfortunately, a leading contributor to the research and a significant
shareholder of the company took medical leave at the height of these efforts.
Complications associated with his illness and absence forced the company to
withdraw from the IPO process.

Initial Results
The results of the Phase 2 clinical trial in men were obtained in mid-2005.
However, although there were positive signals in those results, the results
were confounded by the need to provide supplemental testosterone to men on
active treatment in the trial.

During 2006, Curaxis renewed its efforts to obtain private capital to complete
its Phase 3 trials. Although it enjoyed some success, it was unable to obtain
the full amount needed and was forced to terminate the Phase 3 trials in late
2006. During the remainder of 2006 and 2007, Curaxis worked to obtain the
maximum amount of data from these terminated trials. Although the data was
incomplete due to the early termination of the trials, the date obtained
provided further support for the use of leuprolide to treat mild-to-moderate
Alzheimer's, particularly in women.

During 2008 and 2009, Curaxis has regrouped in its efforts to move forward with
Memryte. Although Curaxis was unable to make progress in the clinical
development of Memryte during this period, the field of Alzheimer's research
was not static during this period. A number of Phase 3 Alzheimer's trials,
which focused on a target called beta amyloid to treat Alzheimer's, failed to
meet their endpoints during 2007-2009. Curaxis has long believed that a focus
solely on beta amyloid as a target to treat Alzheimer's is incorrect and the
failures of these trials support that view. Most importantly, Curaxis believes
that the failure of these trials will broaden acceptance of other approaches to
treating Alzheimer's, including Curaxis' approach.

In 2009, Curaxis entered into a series of agreements with Southridge Business
Solutions Group ("Southridge") in order to restructure its balance sheet and
establish a trading market for its common stock. Under the terms of those
agreements, Southridge assisted Curaxis in negotiating settlements with its
creditors to eliminate or substantially reduce and defer its trade debt. To
date, Curaxis has realized reductions in excess of $6 million in liabilities as
the result of the combined efforts. In addition, Southridge assisted Curaxis in
securing a $25 million equity facility under which the Company can
periodically, over a period of three years, sell up to $25 million of its
common stock to an affiliate of Southridge. On December 8, 2010, the Company
filed a Registration Statement on Form S-1 to register 13,000,000 shares of
common stock to be reserved for issuance under the Equity Line Facility.The
proceeds of the equity facility will be used, in part, to fund the next steps
in the Company's clinical development plan.

In July, 2010, Curaixs completed a reverse merger into a public shell
Corporation. As a result, the Company's common stock is now traded on the OTC
Quote Board under the symbol "CURX." In addition, Curaxis began trading on the
Frankfurt Stock Exchange under the ticker "8CX" on February 7, 2011.

On June 27, 2011, the Company announced changes to its Board of Directors (the
"Board") and its executive management team to better position the Company for
its next phase of growth and development. The new Board has a wealth of
experience and comprehensive knowledge of life sciences, operations and
strategic management in the area of pharmaceuticals. In addition, the newly
appointed Board members have significant experience in all of the necessary
industry arenas to execute the Company's business plan on an accelerated basis.

Going Forward
The Board is in the process of completing a comprehensive analysis of the
financial position of the Company and is evaluating potential funding
alternatives. In addition, the Board has been focused on several remaining
transition items including, but not limited to, the efficient processing of
capital transactions for pre-merger shareholders, the scientific evaluation of
the Company's inventory of pre-clinical and clinical data and related
intellectual property and, the development of strategic alternatives.

DOWNLOAD: Alzheimers Research Report (PDF)
[8]http://www.curaxispharma.com/images/pdf/alzheimers_research_report.pdf

BLOGS [9]http://blog.curaxispharma.com/

Milestones:
[10]http://www.curaxispharma.com/index.php?option=com_content&view=article&id=5
2&Itemid=69
Links:
[11]http://www.curaxispharma.com/index.php?option=com_content&view=article&id=5
4&Itemid=71
Reference:
[12]http://www.curaxispharma.com/index.php?option=com_content&view=article&id=5
5&Itemid=72

CURX Partners
Curaxis has engaged a very impressive infrastructure of scientific/technical,
medical and legal advisers as strategic partners. This allows the Company to
leverage talented individuals who provide key knowledge, expertise and support.
A selection of these partnerships is represented by:

Our collaboration in discovery research with leading Alzheimer's research
teams led by George Perry, PhD, Mark A. Smith, PhD
([13]http://www.cwru.edu/med/pathology);
Leading patent and FDA legal support from Covington & Burling
([14]http://www.cov.com);
Clinical and FDA regulatory support from Bert Spilker & Associates
([15]http://www.bertspilker.com);
Drug development and delivery support from DURECT Corporation
([16]http://www.durect.com);
Website and marketing communications support by Sage Communications, LLC.
([17]http://www.aboutsage.com)

Case Western Reserve University - Department of Pathology
World-class research is conducted in the Department of Pathology with major
emphasis on the following areas and more: cancer biology, infection and
immunity, neurobiology/neuropathology, tissue injury and healing, and
biomaterials biocompatibility. These emphasis areas are reflected in the three
tracks of the Pathology Graduate Program: the Cancer Biology Training Program
(CBTP), the Immunology Training Program (ITP) and the Molecular and Cellular
Basis of Disease Training Program (MCBDTP). The Pathology Graduate Program
provides extensive opportunities for PhD or MD-PhD training in these areas. A
separate program leads to the MS degree.

Covington & Burling LLP
Covington & Burling LLP represents clients in cutting-edge technology,
litigation, white collar defense, transactional, governmental affairs,
international, life sciences and other matters. In responding to the needs and
challenges of our clients, our lawyers draw upon the firm's expertise and
experience in a broad array of industries to provide solutions to difficult,
complex, and novel problems and issues, whether in litigation, transactions, or
regulatory proceedings.

Bert Spilker & Associates
The mission of Bert Spilker & Associates (BS&A) is to provide clients with the
highest quality, most cost-effective, and timely pharmaceutical consulting
services available. To achieve this goal, Bert has assembled a group of over
150 independent associates who are available to assist him in most aspects of
drug discovery, drug development and strategy setting. BS&A strives to build
long-term relationships with clients based on knowledge of his clients culture,
research, products and services.

Sage Communications Advertising and Public Relations
Sage Communications is a full-service, integrated marketing firm that provides
advertising, public relations, and strategic marketing services to clients from
across the street to across the globe, from emerging start-ups, to major
Fortune 500 companies. Throughout our history, our mission has remained the
same: Align marketing strategy to directly impact our clients' bottom line. We
are located in Tysons Corner, VA

CURX Recent News

RED HOTT

The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be
held on November 8th 2011.
Quote:
___________________________________________________________________________

Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company
dedicated to finding cures for major age-related diseases. Curaxis' initial
focu s is Alzheimer's Disease (or AD). The lead product is a patented
treatment, Memryte, that has shown the potential for treating and halting the
progression of this devastating disease.
The Problem
Washington DC, May 19, 2010, A new report from the Alzheimer's Association,
"Changing the Trajectory of Alzheimer's Disease: A National Imperative" shows
that in the absence of disease-modifying treatments, the cumulative cost of
care for people with Alzheimer's from 2010 to 2050 will exceed $20 trillion in
today's dollars.
The new report is not all bad news, however, as it shows that Medicare and
Medicaid can achieve dramatic savings - and lives could be significantly
improved - with even incremental treatment improvements.
Harry John's, President & CEO of the Alzheimer's Association said, " Today,
there are NO treatments that can prevent, delay, slow or stop the progression
of Alzheimer's disease. While the ultimate goal is a treatment that can
completely prevent or cure Alzheimer's, we can see that even modest
improvements can have a huge impact."
Market Need - Curaxis Solution
Currently marketed Alzheimer's drugs target the symptoms of Alzheimer's disease
by enhancing some patients' cognitive function and general behavior, but
generally are not thought to slow progression of the disease.
Only about 50% of patients taking AChEIs (acetylcholinesterase inhibitors -
current theory) experience a modest improvement in cognitive function.
According to the Alzheimer's Association, for those patients who show
improvement, the benefit typically lasts for only six months to one year.
Based on preclinical and clinical results achieved to date, Curaxis believes
that Memryte may substantially slow the progression of Alzheimer's disease and
represent a significant clinical improvement over current drugs.
___________________________________________________________________________

Aug 17, 2011 Curaxis Pharmaceutical Corporation Management Working Through
Transition Phase and Evaluating Alternatives
Jun 27, 2011 Curaxis Pharmaceutical Corporation Announces Key Changes to Its
Board of Directors and Management Team in Progression Toward Clinical Trials
May 10, 2011 Curaxis Pharmaceutical Corporation Chief Executive Officer
Comments on Recent NIH Research
May 5, 2011 Curaxis' Memryte Named One of the Top 100 Drugs in Development
Today by R&D Directions
Mar 24, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on
Recent Prana Research
Mar 10, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on
Recent New York Times Article "Drug Firms Face Billions in Losses in '11 as
Patents End"
Feb 14, 2011 Curaxis Pharmaceutical Corp. to Meet With Ticino Business
Development Office in Lugano, Switzerland
Feb 9, 2011 Curaxis Pharmaceutical Corp. Announces New Listing on the Frankfurt
Stock Exchange
Feb 7, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on
Recent Alzheimer's Association Report
Feb 3, 2011 Curaxis Pharmaceutical Management on Roadshow in Europe to Access
Capital & Pursue Strategic Partners

CURX Core Management Team

Timothy R. Wright - Chairman and Interim Chief Executive Officer
A seasoned executive with over 25 years of life sciences experience, Timothy
Wright has comprehensive operating and strategic management experience, which
encompasses pharmaceuticals, medical device, diagnostics and pharmaceutical
services. Prior to joining Curaxis as Chairman of the Board and interim Chief
Executive Officer, Mr. Wright was a Senior Vice President and President of the
pharmaceuticals division at Covidien (Mallinckrodt). He previously served as
President of Global Operations at Elan BioPharmaceuticals and spent 17 years at
DuPont Merck Pharmaceuticals, where he was classically trained in the
pharmaceutical industry. He brings significant global operating and product
launch experience and has served on the boards of four public and four private
global life sciences companies.

Judith S. T. Geaslen - VP Finance

Judith S. T. Geaslen has been the Company's Vice President of Finance and Chief
Accounting Officer since August 2009 after serving as Corporate Controller and
Accountant since July 2004. From March 1999 to April, 2000, Ms. Geaslen served
as Vice President and Corporate Controller at Wilmington Trust Corporation, a
financial holding company engaged in providing a range of banking and other
financial services through its banking and other subsidiaries, and from 1994 to
1999, served as Vice President and Manager of the Asset Review Division. From
September 1984 to September 1994, Ms. Geaslen was employed by Ernst & Young, a
registered public accounting firm, mostly recently serving as Audit Senior
Manager. Ms. Geaslen is a graduate of Saint Mary's College, Notre Dame,
Indiana.

CURX Contact Info
Curaxis Pharmaceutical Corp
1004 Chagford Way
Raleigh, NC 27614

Website: [18]http://www.curaxispharma.com
Phone: [phone]
Email: [e-mail]
twitter: [19]http://twitter.com/#!/curaxispharma
facebook:
[20]http://www.facebook.com/pages/Curaxis-Pharmaceutical-Corporation/1591043041
05704

As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile,
Always do your own Due Diligence

Sources: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CURX website,
www.businessweek.com
(these are only sources and not always up to date)

___________________________________________________________________________

1 day + weekend Awareness Profile

StockGoodies.com [21] [jpeg]
disclaimer: [22]http://www.stockgoodies.com/terms_of_use.php
Email: [e-mail] // Website: [23]http://www.stockgoodies.com

[24][jpeg] [25] [jpeg] [26] [jpeg]

References

1. https://www.iproxydirect.com/index.php/CURX
2. http://blog.curaxispharma.com/media/
3. http://blog.curaxispharma.com/media/
4. http://www.otcmarkets.com/stock/CURX/quote
5. http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8096721
6. http://www.youtube.com/watch?v=XdMmQ6ppDnU
7. http://www.youtube.com/watch?v=XdMmQ6ppDnU
8. http://www.curaxispharma.com/images/pdf/alzheimers_research_report.pdf
9. http://blog.curaxispharma.com/
10. http://www.curaxispharma.com/index.php?option=com_content&view=article&id=52&Itemid=69
11. http://www.curaxispharma.com/index.php?option=com_content&view=article&id=54&Itemid=71
12. http://www.curaxispharma.com/index.php?option=com_content&view=article&id=55&Itemid=72
13. http://www.cwru.edu/med/pathology);
14. http://www.cov.com%29%3B/
15. http://www.bertspilker.com%29%3B/
16. http://www.durect.com%29%3B/
17. http://www.aboutsage.com%29/
18. http://www.curaxispharma.com/
19. http://twitter.com/#!/curaxispharma
20. http://www.facebook.com/pages/Curaxis-Pharmaceutical-Corporation/159104304105704
21. http://www.stockgoodies.com/
22. http://www.stockgoodies.com/terms_of_use.php
23. http://www.stockgoodies.com/
24. http://investorshub.advfn.com/boards/board.aspx?board_id=18582
25. http://www.facebook.com/StockGoodies
26. http://twitter.com/#!/StockGoodies